CANOE 2010

NCT00116932

1 Treatments

Studied treatment  rosiglitazone (2 mg) and metformin (500 mg) twice-daily

Control treatment  placebo

Concomittant treatments  -

Women (%)  -

Age (mean), years  -

2 Patients

Patients  patients with impaired glucose tolerance

Inclusion criteria  -

Exclusion criteria  -

Weight (kg)  -

Body-mass index (kg/m2)  -

Waist circumference (cm)  -

obesity  -

Family history of diabetes mellitus (%)  -

Definitions of impaired glucose tolerance and type 2 diabetes  -

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  -

Geographical area  -

Sizes  103/104

fasting plasma glucose (mmol/L)  -
Dyslipidaemia

2hPG (>9.4–11.0 mmol/L)

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>hospitalization for heart failure</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death, MI, stroke</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>diabetes</td>
<td>14/70</td>
<td>41/52</td>
<td>0,25</td>
<td>[0,10; 0,62]</td>
</tr>
<tr>
<td>fatal and non fatal MI</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>normoglycemia</td>
<td>70/70</td>
<td>52/52</td>
<td>1,00</td>
<td>[0,00; +Infini]</td>
</tr>
<tr>
<td>fatal and non fatal stroke</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovasculaire events</td>
<td>-/70</td>
<td>-/52</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References